BDBM160490 US10093663, Example 30-3::US9682968, Example-30-2::US9682968, Example-30-3
SMILES: COc1cc(C)c2[nH]ccc2c1CN1CC(O)CCC1c1ccc(cc1)C(O)=O
InChI Key:
Data: 8 IC50
Target/Host (Institution) | Ligand | Target/Host Links | Ligand Links | Trg + Lig Links | Ki nM | ΔG° kcal/mole | IC50 nM | Kd nM | EC50/IC50 nM | koff s-1 | kon M-1s-1 | pH | Temp °C |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Complement factor B (Homo sapiens (Human)) | BDBM160490 (US10093663, Example 30-3 | US9682968, Example-30-2...) | PDB UniProtKB/SwissProt UniProtKB/TrEMBL GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 8.20 | n/a | n/a | n/a | n/a | n/a | n/a |
Novartis AG US Patent | Assay Description CVF-Bb complex prepared from purified cobra venom factor (1 μM), recombinant human complement factor B (expressed in drosophila cells and purifi... | US Patent US9682968 (2017) BindingDB Entry DOI: 10.7270/Q2XG9P9J | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Complement factor B (Homo sapiens (Human)) | BDBM160490 (US10093663, Example 30-3 | US9682968, Example-30-2...) | PDB UniProtKB/SwissProt UniProtKB/TrEMBL GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 1.30 | n/a | n/a | n/a | n/a | n/a | n/a |
Novartis AG US Patent | Assay Description CVF-Bb complex prepared from purified cobra venom factor (1 μM), recombinant human complement factor B (expressed in drosophila cells and purifi... | US Patent US9682968 (2017) BindingDB Entry DOI: 10.7270/Q2XG9P9J | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Complement factor B (Homo sapiens (Human)) | BDBM160490 (US10093663, Example 30-3 | US9682968, Example-30-2...) | PDB UniProtKB/SwissProt UniProtKB/TrEMBL GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 8.20 | n/a | n/a | n/a | n/a | n/a | n/a |
Novartis AG US Patent | Assay Description CVF-Bb complex prepared from purified cobra venom factor (1 μM), recombinant human complement factor B (expressed in drosophila cells and purifi... | US Patent US9682968 (2017) BindingDB Entry DOI: 10.7270/Q2XG9P9J | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Complement factor B (Homo sapiens (Human)) | BDBM160490 (US10093663, Example 30-3 | US9682968, Example-30-2...) | PDB UniProtKB/SwissProt UniProtKB/TrEMBL GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 1.30E+3 | n/a | n/a | n/a | n/a | 7.4 | 25 |
Novartis AG US Patent | Assay Description CVF-Bb complex prepared from purified cobra venom factor (1 μM), recombinant human complement factor B (expressed in drosophila cells and purifi... | US Patent US10093663 (2018) BindingDB Entry DOI: 10.7270/Q2DF6T75 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Complement factor B (Homo sapiens (Human)) | BDBM160490 (US10093663, Example 30-3 | US9682968, Example-30-2...) | PDB UniProtKB/SwissProt UniProtKB/TrEMBL GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 8.20E+3 | n/a | n/a | n/a | n/a | 7.4 | 25 |
Novartis AG US Patent | Assay Description CVF-Bb complex prepared from purified cobra venom factor (1 μM), recombinant human complement factor B (expressed in drosophila cells and purifi... | US Patent US10093663 (2018) BindingDB Entry DOI: 10.7270/Q2DF6T75 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Complement factor B (Homo sapiens (Human)) | BDBM160490 (US10093663, Example 30-3 | US9682968, Example-30-2...) | PDB UniProtKB/SwissProt UniProtKB/TrEMBL GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 1.30E+3 | n/a | n/a | n/a | n/a | 7.4 | 25 |
Novartis AG US Patent | Assay Description CVF-Bb complex prepared from purified cobra venom factor (1 μM), recombinant human complement factor B (expressed in drosophila cells and purifi... | US Patent US10093663 (2018) BindingDB Entry DOI: 10.7270/Q2DF6T75 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Complement factor B (Homo sapiens (Human)) | BDBM160490 (US10093663, Example 30-3 | US9682968, Example-30-2...) | PDB UniProtKB/SwissProt UniProtKB/TrEMBL GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 8.20E+3 | n/a | n/a | n/a | n/a | 7.4 | 25 |
Novartis AG US Patent | Assay Description CVF-Bb complex prepared from purified cobra venom factor (1 μM), recombinant human complement factor B (expressed in drosophila cells and purifi... | US Patent US10093663 (2018) BindingDB Entry DOI: 10.7270/Q2DF6T75 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Complement factor B (Homo sapiens (Human)) | BDBM160490 (US10093663, Example 30-3 | US9682968, Example-30-2...) | PDB UniProtKB/SwissProt UniProtKB/TrEMBL GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 1.30 | n/a | n/a | n/a | n/a | n/a | n/a |
Novartis AG US Patent | Assay Description CVF-Bb complex prepared from purified cobra venom factor (1 μM), recombinant human complement factor B (expressed in drosophila cells and purifi... | US Patent US9682968 (2017) BindingDB Entry DOI: 10.7270/Q2XG9P9J | |||||||||||
More data for this Ligand-Target Pair |